Immix Biopharma, Inc. IMMX Tax Credit Carryforward Valuation Allowance
Tax Credit Carryforward Valuation Allowance at other companies
Other financials
Where this comes from
Reported directly by Immix Biopharma, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DeferredTaxAssetsValuationAllowance.
The official record: Immix Biopharma, Inc.’s 10-K/A, filed March 27, 2026, on SEC EDGAR. View the filing →
Ask your AI about Immix Biopharma, Inc.'s tax credit carryforward valuation allowance.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Immix Biopharma, Inc.'s tax credit carryforward valuation allowance?
- Immix Biopharma, Inc. (IMMX) reported tax credit carryforward valuation allowance of $25.29M in Q4 2025.
- How has Immix Biopharma, Inc.'s tax credit carryforward valuation allowance changed year-over-year?
- Immix Biopharma, Inc.'s tax credit carryforward valuation allowance increased by 60.4% year-over-year, from $15.76M to $25.29M.
- What is the long-term trend for Immix Biopharma, Inc.'s tax credit carryforward valuation allowance?
- Over 5 years (2020 to 2025), Immix Biopharma, Inc.'s tax credit carryforward valuation allowance has grown at a 119.1% compound annual growth rate (CAGR), from $501.42K to $25.29M.
- What does tax credit carryforward valuation allowance mean?
- This is a contra-asset account that reduces the carrying value of tax credit carryforwards when it is more likely than not that some or all of the credits will not be realized. It reflects management's assessment of the company's ability to generate sufficient future taxable income. A high allowance suggests uncertainty regarding the realization of tax benefits.